The therapeutic strategy for peptic ulcer disease

Area of Science:

• Gastroenterology
• Pharmacology
• Internal Medicine

Background:

• Acid/peptic disease therapy has evolved significantly since the 1970s.
• Early treatments focused on reducing gastric acid (aggressive factors).
• Recent understanding emphasizes gastroduodenal mucosal defense mechanisms.

Purpose of the Study:

• To review the evolution of acid/peptic disease treatment.
• To highlight the role of non-steroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori.
• To discuss current therapeutic strategies and ongoing research.

Main Methods:

• Review of historical and current therapeutic approaches.
• Analysis of the impact of technological advancements (endoscopy).
• Examination of the role of aggressive and defensive factors in ulcer pathogenesis.

Main Results:

• Development of histamine H2-receptor antagonists and H+/K(+)-ATPase inhibitors.
• Recognition of NSAIDs as a major cause of peptic ulcers.
• Identification of H. pylori as a key factor in ulcer recurrence, leading to antibiotic/bismuth therapy.

Conclusions:

• Therapeutic strategies have shifted towards addressing mucosal integrity and pathogen eradication.
• Treatment paradigms for H. pylori-associated ulcers are continually evolving.
• Optimal management of initial ulcer presentations remains an area of active investigation.